New immunotherapy cocktail aims to tackle tough lung cancer

NCT ID NCT07245446

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether adding extra immunotherapy drugs to standard chemotherapy can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, all receiving the immunotherapy ivonescimab plus chemo, with some also getting cadonilimab or AK117. The goal is to see which combination shrinks tumors most safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ivonescimab (an immunotherapy drug) combined with chemotherapy (etoposide and carboplatin) and optionally cadonilimab or AK117
What this could lead to: If successful, this could offer a new first-line treatment option that shrinks tumors and controls extensive-stage small cell lung cancer for longer.
What could go wrong: This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. Side effects from combining multiple drugs could be significant, and the added drugs may not improve outcomes over standard chemo-immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100020, China
Shanghai Pulmonary Hospital Affiliated to Tongji University
RECRUITING

Shanghai, Shanghai Municipality, 200433, China
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.